Scott Gottlieb [via AP]

Scott Got­tlieb tempts the FDA's fiercest crit­ics with his leap on­to Pfiz­er's board of di­rec­tors

The next chap­ter of Scott Got­tlieb’s ca­reer will be played out in the in­ner sanc­tums of Big Phar­ma — for­ev­er re­in­forc­ing the FDA’s crit­ics of the re­volv­ing door be­tween the agency and the in­dus­try.

Af­ter the mar­ket closed on Thurs­day, Pfiz­er — the biggest of the big — said that the ex-com­mis­sion­er had been elect­ed to its board of di­rec­tors. That comes on top of his roles as a spe­cial ven­ture part­ner at New En­ter­prise As­so­ciates and reg­u­lar com­men­ta­tor on all things drug-re­lat­ed for the con­ser­v­a­tive Amer­i­can En­ter­prise In­sti­tute, where he’s be­come a high-pro­file fig­ure.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.